Search Results - "Lincoff AM"

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

Authors: Topol EJ Mark DB Lincoff AM et al.

Source: Lancet. 12/11/1999, Vol. 354 Issue 9195, p2019-2024. 6p.

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

Authors: Henry RR Lincoff AM Mudaliar S et al.

Source: Lancet. 7/11/2009, Vol. 374 Issue 9684, p126-135. 10p.

Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction.

Authors: Aronow HD Lincoff AM Quinn MJ et al.

Source: American Journal of Cardiology. Nov2008 Supplement, Vol. 102 Issue 9, p1119-1124. 6p.

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

Authors: Lincoff AM Wolski K Nicholls SJ et al.

Source: JAMA: Journal of the American Medical Association. 9/12/2007, Vol. 298 Issue 10, p1180-1188. 9p.

Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.

Authors: Stone GW White HD Ohman EM et al.

Source: Lancet. 3/17/2007, Vol. 369 Issue 9565, p907-919. 13p.

Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.

Authors: Saw J Lincoff AM DeSmet W et al.

Source: Journal of the American College of Cardiology (JACC). Sep2004, Vol. 44 Issue 6, p1194-1199. 6p.

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIa receptors.

Authors: Lincoff AM Califf RM Moliterno DJ et al.

Source: New England Journal of Medicine. 07/29/99, Vol. 341 Issue 5, p319-327. 9p.

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors: Vandvik PO Lincoff AM Gore JM et al.

Source: CHEST. Feb2012 Supplement 2, Vol. 141, pe637S-68S. 1p.

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Authors: White HD Ohman EM Lincoff AM et al.

Source: Journal of the American College of Cardiology (JACC). Sep2008, Vol. 52 Issue 10, p807-814. 8p.

Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes.

Authors: Bhatt DL Chew DP Lincoff AM et al.

Source: American Journal of Cardiology. Jul2003, Vol. 92 Issue 2, p136-140. 5p.

Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations.

Authors: Cho L Kottke-Marchant K Lincoff AM et al.

Source: American Journal of Cardiology. May2003, Vol. 91 Issue 9, p1110-1113. 4p.

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors: Jneid H Anderson JL Wright RS et al.

Source: Circulation. 8/14/2012, Vol. 126 Issue 7, p875-910. 36p.

2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors: Wright RS Anderson JL Adams CD et al.

Source: Journal of the American College of Cardiology (JACC). May2011, Vol. 57 Issue 19, p1920-1959. 40p.

Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Authors: Prasad A Gersh BJ Bertrand ME et al.

Source: Journal of the American College of Cardiology (JACC). Jul2009, Vol. 54 Issue 5, p477-486. 10p.

Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Authors: White HD Chew DP Hoekstra JW et al.

Source: Journal of the American College of Cardiology (JACC). May2008, Vol. 51 Issue 18, p1734-1741. 8p.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Authors: Nissen SE Nicholls SJ Wolski K et al.

Source: JAMA: Journal of the American Medical Association. 4/2/2008, Vol. 299 Issue 13, p1561-1573. 13p.

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Authors: Nissen SE Nicholls SJ Wolski K et al.

Source: JAMA: Journal of the American Medical Association. 4/2/2008, Vol. 299 Issue 13, p1547-1560. 14p.

Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.

Authors: Stone GW Ware JH Bertrand ME et al.

Source: JAMA: Journal of the American Medical Association. 12/5/2007, Vol. 298 Issue 21, p2497-2506. 10p.

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

Authors: Stone GW Bertrand ME Moses JW et al.

Source: JAMA: Journal of the American Medical Association. 2/14/2007, Vol. 297 Issue 6, p591-602. 12p.

Bivalirudin for patients with acute coronary syndromes.

Authors: Stone GW McLaurin BT Cox DA et al.

Source: New England Journal of Medicine. 11/23/2006, Vol. 355 Issue 21, p2203-2272. 18p.